Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Teva Identifier
TV48125-CNS-30084
ClinicalTrials.gov Identifier
NCT04530110
Study Status
Active, not recruiting
Trial Condition(s)
Migraine
Interventions
Drug: Fremanezumab
EudraCT Number
2019-002056-16
Study Description
Primary objectives: The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study).
Secondary objectives: Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed to fremanezumab.
The total duration of the study is planned to be up to 60 months.
You are about to leave the Teva Pharmaceuticals global website
The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit.
Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites.